Pipeline
Advancing a novel product candidate for cardiometabolic disorders
Developing ninerafaxstat in three high value cardiometabolic indications.
Phase 2 clinical trials have been completed in non-obstructive hypertrophic cardiomyopathy (nHCM), stable angina, and early-stage heart failure with preserved ejection fraction (pre-HFpEF). We are currently recruiting HFpEF patients for IMPROVE-DiCE Part 2.
